Data from a trial seeking to determine whether multiple injections of a tuberculosis vaccine developed in the 1900s could protect high-risk diabetes patients from COVID produced some positive results, according to a New York Times report. The trial tracked COVID infections among a group of 144 participants all of whom had Type 1 diabetes, with two-thirds receiving at least 3 doses of BCG, or Bacillus-Calmette-Guerin, shots, which protect people by bolstering the immune system. The results...


Become a member to take advantage of more features, like commenting and voting.

Jobs to Watch